Who are Ambisome and Paromomycin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ambisome-and-paromomycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Ambisome and Paromomycin — Competitive Intelligence Brief

Ambisome and Paromomycin (Ambisome and Paromomycin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifungal and antiparasitic combination. Area: Infectious Disease.

phase 3 Antifungal and antiparasitic combination Fungal ergosterol; parasitic 30S ribosomal subunit Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ambisome and Paromomycin (Ambisome and Paromomycin) — Drugs for Neglected Diseases. Ambisome (liposomal amphotericin B) disrupts fungal cell membranes by binding ergosterol, while paromomycin is an aminoglycoside antibiotic that inhibits protein synthesis in parasites.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ambisome and Paromomycin TARGET	Ambisome and Paromomycin	Drugs for Neglected Diseases	phase 3	Antifungal and antiparasitic combination	Fungal ergosterol; parasitic 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifungal and antiparasitic combination class)

Drugs for Neglected Diseases · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ambisome and Paromomycin — Competitive Intelligence Brief. https://druglandscape.com/ci/ambisome-and-paromomycin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab